Plasmapp
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Plasmapp makes plasma-based sterilisation systems, devices that use ionised gas to kill pathogens on surgical instruments quickly and at low temperatures, along with surface-activation and dental-treatment devices built on the same core plasma technology.
Its products are used in hospitals and clinics of varying sizes, with its sterilisation line targeting mid-sized surgical centres and specialty clinics rather than only large general hospitals. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's sterilisation product line is its primary commercial focus, offered in multiple configurations under a single product family.
Summary is AI-generated and may contain errors · figures from DART filings
Plasmapp was founded out of a physics laboratory at KAIST, one of Korea's leading science and technology universities, giving it an academic research origin uncommon among listed medical-device companies.
Plasmapp in five facts
What does Plasmapp do?
Plasmapp makes plasma-based sterilisation systems, devices that use ionised gas to kill pathogens on surgical instruments quickly and at low temperatures, along with surface-activation and dental-treatment devices built on the same core plasma technology.
Where is Plasmapp listed and in which sector?
Plasmapp (Korean name: 플라즈맵) trades under KRX code 405000 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Plasmapp?
Its market capitalisation was US$15.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Plasmapp's latest annual revenue and operating profit?
For fiscal year 2025, Plasmapp reported revenue of US$6.4M, an operating loss of US$5.7M and a net loss of US$5M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 16.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 2
- Material event report (rights offering)
Plasmapp disclosed a private placement (third-party allotment) to raise US$4.75M, about 34.6% of its market value.
Capital raise · Jul 23 - Supply contract signed
Plasmapp disclosed a supply contract with Qmed Master Distribution, worth US$2.3M, about 41.63% of its recent annual revenue, running through Jun 2027.
Supply contract · Jun 4 - Supply contract signed
Plasmapp disclosed a supply contract with MegaGen Implant Co., Ltd., worth US$1.66M, about 24.66% of its recent annual revenue, running through Mar 2027.
Supply contract · Mar 31 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Plasmapp reported consolidated results for FY2025: revenue of US$5.89M (−16.3% year on year), an operating loss of US$5.28M and a net loss of US$4.57M.
Earnings · Feb 25